What did idelalisib trials test, and in which diseases?
Idelalisib was studied in clinical trials for blood cancers, especially chronic lymphocytic leukemia (CLL) and certain non-Hodgkin lymphomas, where it targets the PI3K-delta pathway. Across trials, clinicians evaluated how well idelalisib works as a treatment (often in combination regimens) and how safe it is for people with these malignancies. [1]
How long were idelalisib trials, and what endpoints were measured?
Trials involving idelalisib generally tracked response and how long responses lasted, using endpoints such as objective response and progression-related outcomes, alongside safety monitoring (adverse events, lab changes, and infections). The exact duration and endpoints vary by study, phase, and whether idelalisib was tested alone or with other drugs. [1]
What side effects did idelalisib trials report most often?
Across idelalisib studies, safety reporting focused on treatment-related adverse events, including risks associated with immune effects of PI3K-delta inhibition and the development of infections. Trial publications and summaries typically emphasize monitoring for these complications during treatment. [1]
Were idelalisib results compared against standard therapy or placebo?
Idelalisib trial designs ranged from randomized comparisons to single-arm studies, depending on the phase and disease setting. Where comparative trials were run, outcomes were benchmarked against a control arm or standard-of-care regimen; where single-arm studies were used, results were assessed against historical expectations and predefined response criteria. [1]
What should I look for in an “idelalisib trial” record (so I can judge the evidence)?
When you search for an idelalisib trial, useful details include:
- Trial phase (how early or late the evidence is)
- Study design (randomized vs single-arm)
- Disease subtype and line of therapy (treatment-naive vs relapsed/refractory)
- Combination partners (if any)
- Primary endpoints (response rate vs progression metrics)
- Safety findings, especially infection and immune-related toxicities
Those elements determine whether the evidence is strong for your specific disease setting. [1]
Where can I find specific idelalisib trial listings?
The most reliable way to find exact trial details (protocol, eligibility, start/completion dates, and results when available) is to use clinical trial registries and publications linked to idelalisib studies, such as the U.S. National Library of Medicine’s clinical trials database. [1]
---
Sources
[1] https://clinicaltrials.gov/ (search “idelalisib”)